Target intelligence / Profile preview

Endogenous microRNA-720-complementary messenger RNAs (miR-720 targets)

Target
miR-720 targets
Molecular classification
Messenger RNA, Nucleic acid
01

Overview

Endogenous microRNA-720-complementary messenger RNAs (mRNAs) are a group of transcripts regulated by miR-720, a small non-coding RNA. While originally classified as a microRNA, miR-720 is now recognized as a tRNA-derived small RNA (tsRNA) originating from the 5' end of tRNA-Thr (Schopman et al., 2010). These mRNAs are regulated through sequence-specific binding, typically in their 3' untranslated regions (UTRs), which results in post-transcriptional gene silencing via the RNA-induced silencing complex (RISC) (Ji et al., 2012). Significant targets include mRNAs for CD44, ZEB2, and HERPUD1, which play vital roles in cell surface signaling, the epithelial-mesenchymal transition, and cellular stress responses (Li et al., 2014). The interaction between miR-720 and these mRNAs is frequently dysregulated in diseases such as breast cancer, pancreatic cancer, and myelodysplastic syndromes, where it impacts cell proliferation and metastasis (Sun et al., 2017). Therapeutic approaches focus on modulating these target levels using synthetic miR-720 mimics or antagomirs to restore normal cellular function.

Other names
miR-720 targetsMicroRNA-720 targetstRNA-Thr fragment targetstRNA-derived small RNA 720 targets
02

Mechanism of action

miR-720 or its tRNA-derived fragment equivalent binds to complementary sequences in the 3' untranslated region (UTR) of target mRNAs, facilitating their degradation or inhibiting their translation through the RNA-induced silencing complex (RISC).

03

Biological functions

Post-transcriptional gene silencingCell proliferationCell differentiationApoptosisEpithelial-mesenchymal transition
04

Disease associations

CancerMyelodysplastic syndromeInflammation
05

Safety considerations

Off-target silencing of non-intended mRNAsSaturation of endogenous RNAi machineryTissue-specific delivery challengesPotential immunogenicity of synthetic RNA therapeutics
06

Interacting drugs

miR-720 mimics

2 more in the full profile.

07

Biomarkers

miR-720 expression levelCD44 expressionZEB2 expression

Beyond the preview

Go deeper on Endogenous microRNA-720-complementary messenger RNAs (miR-720 targets).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogenous microRNA-720-complementary messenger RNAs (miR-720 targets).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call